Oramed Pharmaceuticals (NASDAQ:ORMP) Lowered to “Sell” Rating by StockNews.com

StockNews.com downgraded shares of Oramed Pharmaceuticals (NASDAQ:ORMP) from a hold rating to a sell rating in a research note published on Saturday.

Oramed Pharmaceuticals Stock Performance

Shares of NASDAQ:ORMP opened at $2.14 on Friday. The business’s fifty day moving average price is $2.24 and its two-hundred day moving average price is $2.30. The stock has a market cap of $87.42 million, a PE ratio of 19.45 and a beta of 1.65. Oramed Pharmaceuticals has a one year low of $1.82 and a one year high of $3.09.

Oramed Pharmaceuticals (NASDAQ:ORMP) last issued its quarterly earnings results on Thursday, May 15th. The biotechnology company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.16). The business had revenue of $2.00 million during the quarter. As a group, equities research analysts predict that Oramed Pharmaceuticals will post -0.03 earnings per share for the current fiscal year.

Institutional Trading of Oramed Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. BML Capital Management LLC boosted its stake in Oramed Pharmaceuticals by 14.3% in the first quarter. BML Capital Management LLC now owns 3,020,748 shares of the biotechnology company’s stock valued at $6,464,000 after acquiring an additional 376,841 shares during the period. Boothbay Fund Management LLC raised its holdings in Oramed Pharmaceuticals by 2.0% during the fourth quarter. Boothbay Fund Management LLC now owns 845,188 shares of the biotechnology company’s stock worth $2,045,000 after purchasing an additional 16,857 shares in the last quarter. Peapod Lane Capital LLC raised its holdings in Oramed Pharmaceuticals by 11.0% during the first quarter. Peapod Lane Capital LLC now owns 252,224 shares of the biotechnology company’s stock worth $540,000 after purchasing an additional 24,985 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in Oramed Pharmaceuticals by 143.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 118,995 shares of the biotechnology company’s stock worth $288,000 after purchasing an additional 70,190 shares in the last quarter. Finally, Jane Street Group LLC increased its holdings in shares of Oramed Pharmaceuticals by 35.3% in the first quarter. Jane Street Group LLC now owns 67,173 shares of the biotechnology company’s stock valued at $144,000 after buying an additional 17,510 shares in the last quarter. 12.73% of the stock is owned by hedge funds and other institutional investors.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.